Adicet Bio Files 8-K on Security Holder Vote

TL;DR

Adicet Bio (ACET) is having a shareholder vote on Dec 19, 2025.

AI Summary

On December 19, 2025, Adicet Bio, Inc. filed an 8-K report. The filing indicates that the company is submitting matters to a vote of its security holders. No specific details regarding the nature of the vote or the matters to be voted on were provided in the excerpt.

Why It Matters

This filing signals a corporate action requiring shareholder approval, which could impact the company's future direction or governance.

Risk Assessment

Risk Level: low — The filing is a standard procedural report and does not contain information that inherently increases risk.

Key Players & Entities

• Adicet Bio, Inc. (company) — Registrant
• December 19, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• Boston, Massachusetts (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ACET The Nasdaq Capital M

Filing Documents

• acet-20251219.htm (8-K) — 52KB
• 0001193125-25-326784.txt ( ) — 157KB
• acet-20251219.xsd (EX-101.SCH) — 26KB
• acet-20251219_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On December 19, 2025, Adicet Bio, Inc., a Delaware corporation (the "Company") held its 2025 Special Meeting of Stockholders (the "Special Meeting"). At the Special Meeting, the Company's stockholders considered and voted on the two proposals set forth below, each of which is described in greater detail in the Company's definitive proxy statement on Schedule 14A, which was filed with the U.S. Securities and Exchange Commission on November 17, 2025. The final voting results are set forth below. Proposal 1 – Approval of Reverse Stock Split The stockholders of the Company approved the amendment to the Company's Restated Certificate of Incorporation to combine outstanding shares of the Company's common stock, par value $0.0001 per share, into a lesser number of outstanding shares, by a ratio of not less than one-for-five and not more than one-for-thirty, with the exact ratio to be set within this range by the Company's board of directors in its sole discretion. The results of the stockholders' vote with respect to such approval were as follows: Votes For Votes Against Abstain Broker Non-Votes 111,115,503 2,752,862 117,502 N/A The proposal to adjourn the Special Meeting, if necessary, to permit further solicitation and vote of proxies in the event that there was insufficient votes in favor of Proposal 1, was not acted upon at the Special Meeting since there was sufficient votes to approve Proposal 1.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ADICET BIO, INC. Date: December 19, 2025 By: /s/ Nick Harvey Name: Nick Harvey Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR